Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Chemical Compound Review:

BW-501C N'-[3-(2- chlorophenoxy)propyl]-2...

Synonyms: BW501, BW 501, BW 501C, AC1L58RM, BW 501C67, ...

This record was replaced with 172196.

Chaouloff, F. et al., Boothman, L.J. et al., Tutton, P.J. et al., Docherty, J.R., Vayssettes-Courchay, C. et al.

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

High impact information on N'-[3-(2-chlorophenoxy)propyl]-2-phenylazanyl-ethanimidamide

4. Pretreatment with the peripherally acting 5-HT(2) receptor antagonist BW 501C67 (0.1 mg kg(-1) i.v.) had no effect on the DOI-induced inhibition of 5-HT cell firing, but completely blocked the DOI-induced rise in mean arterial blood pressure [1].
Pretreatment with the 5-HT1C receptor agonist/5-HT2 receptor antagonist m-chlorophenylpiperazine (1 mg/kg i.v.) tended to decrease the EPI-releasing effect of d-Fen, whereas that with the peripheral 5-HT1C/5-HT2 receptor antagonist BW 501C67 (0.5 mg/kg i.v.) did not alter the EPI-releasing effect of d-Fen [2].
However, the antiserotoninergic drug BW 501C and the histamine H2-receptor antagonist cimetidine each caused short-term suppression of tumour growth [3].

Gene context of N'-[3-(2-chlorophenoxy)propyl]-2-phenylazanyl-ethanimidamide

The blood pressure lowering effects of LY 53857 were unaffected by the peripherally acting 5-HT2 receptor antagonist BW 501C [4].

Analytical, diagnostic and therapeutic context of N'-[3-(2-chlorophenoxy)propyl]-2-phenylazanyl-ethanimidamide

These effects were prevented by microinjections of the 5-HT2 receptor antagonists, LY 53857 or BW 501C [5].

References

Evidence that central 5-HT2A and 5-HT2B/C receptors regulate 5-HT cell firing in the dorsal raphe nucleus of the anaesthetised rat. Boothman, L.J., Allers, K.A., Rasmussen, K., Sharp, T. Br. J. Pharmacol. (2003) [Pubmed]
Central 5-hydroxytryptamine2 receptors are involved in the adrenal catecholamine-releasing and hyperglycemic effects of the 5-hydroxytryptamine indirect agonist d-fenfluramine in the conscious rat. Chaouloff, F., Gunn, S.H., Young, J.B. J. Pharmacol. Exp. Ther. (1992) [Pubmed]
Influence of biogenic amines on the growth of xenografted human colorectal carcinomas. Tutton, P.J., Steel, G.G. Br. J. Cancer (1979) [Pubmed]
An investigation of the effects of intravenous injection of the 5-hydroxytryptamine 2 receptor antagonists ketanserin and LY 53857 on blood pressure in anesthetized spontaneously hypertensive rats. Docherty, J.R. J. Pharmacol. Exp. Ther. (1989) [Pubmed]
Cardiovascular effects of microinjections of quipazine into nuclei of the medulla oblongata in anaesthetized cats: comparison with L-glutamate. Vayssettes-Courchay, C., Bouysset, F., Verbeuren, T.J., Schmitt, H., Laubie, M. Eur. J. Pharmacol. (1992) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.